By Amy NortonHealthDay Reporter
WEDNESDAY,Jan. 27, 2016 (HealthDay News) — A newer drug used for preventing organ rejection might improve the long-term outlook for kidney transplant recipients, or a recent study finds.
Over seven years,patients given the drug belatacept (brand name: Nulojix) were 43 percent less likely to die or see their donor kidney fail compared [...]
Source: health.com